CytomX Therapeutics Inc (CTMX) Q2 2024 Earnings Report

CytomX Therapeutics reported QQ2 2024 results with meaningful topline revenue driven by collaboration activities, alongside ongoing clinical development of its PROBODY pipeline. Revenue for the quarter was $25.1 million, up modestly YoY versus Q2 2023 but down sharply QoQ from the prior quarter’s elevated level, reflecting typical quarterly variability in collaboration-driven receipts. The company posted a net loss of $6.53 million and an operating loss of $8.45 million, with a 100% gross margin on reported revenue due to recognition of collaboration-related revenue without corresponding COGS in this early-stage business model. Cash, cash equivalents and investments stood at approximately $137 million at 6/30/2024, positioning CytomX to fund operations into late-2025 absent additional milestones or new deals. Management emphasized disciplined cost control while advancing a multi-modality PROBODY program slate, including CX-904 (masked EGFR-CD3 T-cell engager), CX-2051 (EpCAM-directed PROBODY ADC), and CX-801 (masked interferon alpha 2B PROBODY cytokine). Management reiterated catalysts and data cadence through 2024–2025, including a CX-904 update by year-end 2024, initial CX-2051 data in H1 2025, and initial CX-801 data in H2 2025, with more than 10 collaborations underpinning milestone opportunities. This note evaluates how the pipeline trajectory, balance sheet dynamics, and near-term milestones shape CytomX’s risk/return profile for investors.